3.84
-0.18(-4.48%)
Currency In USD
| Previous Close | 4.02 |
| Open | 3.9 |
| Day High | 3.96 |
| Day Low | 3.75 |
| 52-Week High | 8.87 |
| 52-Week Low | 3.75 |
| Volume | 60,832 |
| Average Volume | 98,413 |
| Market Cap | 145.97M |
| PE | -2.4 |
| EPS | -1.6 |
| Moving Average 50 Days | 5.09 |
| Moving Average 200 Days | 5.92 |
| Change | -0.18 |
If you invested $1000 in Orchestra BioMed Holdings, Inc. (OBIO) since IPO date, it would be worth $336.84 as of March 14, 2025 at a share price of $3.84. Whereas If you bought $1000 worth of Orchestra BioMed Holdings, Inc. (OBIO) shares 3 years ago, it would be worth $388.27 as of March 14, 2025 at a share price of $3.84.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Orchestra BioMed to Present at Upcoming Investor Conferences
GlobeNewswire Inc.
Feb 20, 2025 1:00 PM GMT
NEW HOPE, Pa., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, t
Orchestra BioMed Appoints Vivek Reddy, M.D. as Executive Chairman of the BACKBEAT Study Steering Committee and Chairman of Bioelectronic Therapies Scientific Advisory Board
GlobeNewswire Inc.
Feb 18, 2025 1:00 PM GMT
The BACKBEAT global pivotal study is currently enrolling patients to evaluate the efficacy and safety of atrioventricular interval modulation (“AVIM”) therapy for patients who have uncontrolled hypertension and a pacemaker indicationA globally recogn
Orchestra BioMed Announces Data Demonstrating Favorable Impact of AVIM Therapy on Diastolic Dysfunction, a Key Driver of Heart Failure Progression, will be Presented as Late-Breaking Science at the THT 2025 Conference
GlobeNewswire Inc.
Feb 12, 2025 3:43 PM GMT
Late-breaking oral presentation features echocardiographic data analysis showing favorable impact of AVIM therapy on MODERATO II study patients with diastolic dysfunction, a key component in the development of heart failureHypertension is the leading